News
VERV
6.13
+2.17%
0.13
Weekly Report: what happened at VERV last week (0422-0426)?
Weekly Report · 3d ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
NASDAQ · 04/25 12:50
12 Health Care Stocks Moving In Tuesday's After-Market Session
180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. ABVC BioPharma and Medpace Hldgs stock increased by 5.15%. Fresh2 Group shares fell 12.9% during the session.
Benzinga · 04/23 20:31
Weekly Report: what happened at VERV last week (0415-0419)?
Weekly Report · 04/22 09:32
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of investors of Verve Therapeutics, Inc. For violations of the securities laws. The firm is a leading shareholder rights litigation firm in the U.S. The company is called Verve.
Barchart · 04/19 09:30
Weekly Report: what happened at VERV last week (0408-0412)?
Weekly Report · 04/15 09:29
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its weakness. Verve Therapeutics Inc is one of the major oversold players in this sector.
Benzinga · 04/11 12:46
VERVE THERAPEUTICS INC <VERV.O>: JEFFERIES CUTS TARGET PRICE TO $31 FROM $75
Reuters · 04/10 04:03
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
TipRanks · 04/08 10:25
VERVE THERAPEUTICS, INC. <VERV.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $15
Reuters · 04/08 10:04
Weekly Report: what happened at VERV last week (0401-0405)?
Weekly Report · 04/08 09:31
After a Serious Setback, Is Verve Therapeutics a Buy?
Verve Therapeutics saw its shares crater by 36% on April 2 after a serious mishap in one of its clinical trials. The gene-editing biotech's lead program, VERVE-101, is intended to treat a hereditary disease. The company is now focusing its efforts on a different candidate.
The Motley Fool · 04/06 13:50
Top 10 worst performing Cathie Wood ARKK holdings of 2024
Cathie Wood’s flagship ARK Innovation ETF (ARKK) continues its downward struggle this week despite a move higher on Friday afternoon. The innovation focused tech focused ETF currently trades lower on the week by 5.3% and down on the year by 8.7%. The fund is constructed of 37 names of which only 10 trade in positive territory in 2024. 27 of the top 10 worst performing names in ARKK's portfolio are tech companies.
Seeking Alpha · 04/05 18:32
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
Cathie Wood-led Ark Invest sold shares of Coinbase Global Inc (NASDAQ:COIN) on Thursday. The value of the trade amounted to approximately $6.4 million. Ark Invest's decision to offload shares came despite the stock's positive market performance on the same day. Oppenheimer raised its share price target for Coinbase to $276.
Benzinga · 04/05 03:03
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
NASDAQ · 04/04 17:21
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Cathie Wood’s Ark Invest purchased 26,925 shares of Pinterest Inc (NYSE:PINS) on Wednesday. The investment firm made the purchase at a value of $949,914. Ark Invest has previously purchased over $23 million worth of Pinterest shares in February.
Benzinga · 04/04 02:17
Verve Therapeutics: An Update On Human CRISPR
Verve Therapeutics is targeting patients with genetically-driven high cholesterol levels. They are making a single A-to-G change in the gene for the PCSK9 protein. The company announced their results of a human trial of a single-base editing CRISPR therapy yesterday. The first five patients in the trial showed strong and significant cholesterol lowering. The sixth patient showed elevated liver enzyme levels and severe thrombocytopenia.
Seeking Alpha · 04/03 18:15
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
NASDAQ · 04/03 17:40
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Verve Therapeutics, Inc. Has paused enrollment of its drug VERVE-101 after a grade 3 adverse event. The company has decided to move on to its other asset VERve-102, which also targets PCSK9. Despite this setback, the company remains a " hold" for the stock. Partnership with Eli Lilly remains in place for now.
Seeking Alpha · 04/03 15:57
Verve Therapeutics Price Target Cut to $40.00/Share From $56.00 by Stifel
Dow Jones · 04/03 12:57
More
Webull provides a variety of real-time VERV stock news. You can receive the latest news about Verve Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VERV
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.